7,577 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 7,577 shares of the company's stock, valued at approximately $322,000.

A number of other large investors also recently modified their holdings of WGS. Acadian Asset Management LLC bought a new stake in GeneDx during the second quarter worth $34,000. nVerses Capital LLC bought a new stake in shares of GeneDx in the 2nd quarter valued at about $50,000. CWM LLC acquired a new stake in GeneDx in the 3rd quarter valued at about $89,000. American Century Companies Inc. grew its holdings in GeneDx by 36.1% during the second quarter. American Century Companies Inc. now owns 17,258 shares of the company's stock worth $451,000 after purchasing an additional 4,573 shares during the period. Finally, SG Americas Securities LLC acquired a new position in GeneDx during the third quarter worth approximately $198,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. BTIG Research upped their price objective on shares of GeneDx from $35.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, July 31st. TD Cowen raised their price objective on shares of GeneDx from $46.00 to $50.00 and gave the stock a "buy" rating in a research report on Wednesday, July 31st. Craig Hallum boosted their price objective on GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Wells Fargo & Company increased their target price on GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group lifted their price target on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $59.33.

Insider Activity

In related news, Director Jason Ryan sold 31,510 shares of GeneDx stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $71.28, for a total value of $2,246,032.80. Following the transaction, the director now directly owns 15,490 shares of the company's stock, valued at $1,104,127.20. The trade was a 67.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Katherine Stueland sold 3,639 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $121,287.87. Following the transaction, the chief executive officer now owns 95,457 shares of the company's stock, valued at approximately $3,181,581.81. The trade was a 3.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,097,090 shares of company stock valued at $81,094,171. Insiders own 27.30% of the company's stock.

GeneDx Price Performance

Shares of WGS stock traded up $6.64 on Friday, reaching $78.71. The company had a trading volume of 549,559 shares, compared to its average volume of 812,795. The business's 50-day moving average is $59.61 and its 200 day moving average is $39.69. GeneDx Holdings Corp. has a one year low of $1.41 and a one year high of $89.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $2.16 billion, a PE ratio of -25.31 and a beta of 2.11.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to analysts' expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. GeneDx's revenue was up 44.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.82) EPS. Equities research analysts forecast that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.